N4 Pharma PLC on Thursday reported that its novel delivery system for cancer treatment has shown promise, after a successful trial.
The Derbyshire, England-based pharmaceutical company focused on the development of Nuvec, has undergone further testing through its research programme with the University of Queensland.
Nuvec is a new delivery system for cancer treatments and vaccines. The testing was intended to show the successful delivery of a Nuvec capsule into the intestine, demonstrating the potential for Nuvec as an oral delivery system for multiple nucleotide payloads.
In the experiment, an enterically coated capsule was administered on day 0, followed by more capsules on day 3, 6, 9 and a booster capsule on day 21. N4 Pharma found the targeted protein expression was significantly higher in this study than its control study.
Chief Executive Officer Nigel Theobald said: ‘We will continue to scope out the work needed to explore a potential development program focusing on a specific oral application, and further news on this will be announced when a programme is identified. In the meantime, the University of Queensland will continue its work as part of our Australian Research Council funded grant with them.’
N4 Pharma shares were up 7.9% to 0.89 pence each in London on Thursday afternoon.
Copyright 2024 Alliance News Ltd. All Rights Reserved.
